Table 2.
Days of Therapy Negative Binomial Regression Model
| Variable | Rate Ratio | (95% CI) | P Value |
|---|---|---|---|
|
| |||
| Implementation group | |||
| Pre-I (Ref) | 1 | … | |
| Post-I | 0.34 | (.26–.44) | <.01 |
| Age | 1.0 | (.98–1.03) | .77 |
| Sex | |||
| Male (Ref) | 1 | … | |
| Female | 1.0 | (.98–1.0) | .77 |
| Race | |||
| White (Ref) | 1 | … | |
| Asian | 0.93 | (.50–1.85) | .80 |
| Black | 1.21 | (.87–1.69) | .27 |
| Other | 0.86 | (.53–1.44) | .54 |
| Underlying diagnosis | |||
| ALL (Ref) | 1 | … | |
| AML | 0.87 | (.64–1.16) | .33 |
| Othera | 0.81 | (.58–1.13) | .21 |
| Conditioning regimen | |||
| Myeloablative (Ref) | 1 | … | |
| Reduced intensity | 1.0 | (.64–1.53) | .98 |
| Nonmyeloablative | 1.10 | (.41–3.14) | .85 |
Statistically significant P-values (P < 0.05) are shown in bold.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CI, confidence interval; Post-I, postimplementation; Pre-I, preimplementation.
Other underlying diagnoses include: acute megakaryocytic leukemia (6), acute myelomonocytic leukemia (3), acute promyelocytic leukemia (1), mixed phenotype acute leukemia (6), chronic myeloid leukemia (1), diffuse large B-cell lymphoma (1), Hodgkin lymphoma (3), myelodysplastic syndrome (6), myeloid sarcoma (1), other unclassified leukemia or lymphoma (3), aplastic anemia (4), hemophagocytic lymphohistiocytosis (1), myeloid aplasia (1), sickle cell disease (5), embryonal rhabdomyosarcoma (1), Ewing sarcoma (1), neuroblastoma (1).